Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
about
Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspectiveCost-effectiveness of vaccination against herpes zoster.Health economic evaluation of vaccination strategies for the prevention of herpes zoster and postherpetic neuralgia in Germany.The humanistic, economic and societal burden of herpes zoster in Europe: a critical reviewPreventing Chronic Pain following Acute Pain: Risk Factors, Preventive Strategies, and their Efficacy.Systematic review of models assessing the economic value of routine varicella and herpes zoster vaccination in high-income countries.Methods for Health Economic Evaluation of Vaccines and Immunization Decision Frameworks: A Consensus Framework from a European Vaccine Economics CommunityA systematic review of the cost effectiveness of herpes zoster vaccination.Shingles (herpes zoster) vaccine (zostavax(®)): a review of its use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years.Preventing and managing herpes zoster: key actions to foster healthy aging.Herpes zoster vaccine: A health economic evaluation for Switzerland.COST-EFFECTIVENESS ANALYSIS OF HERPES ZOSTER VACCINATION IN ITALIAN ELDERLY PERSONS.Immunogenicity of Varicella Vaccine and Immunologic Predictors of Response in a Cohort of Elderly Nursing Home Residents.Clinical and economic impact of herpes zoster vaccination in elderly in Italy.Vaccination against herpes zoster and postherpetic neuralgia in France: a cost-effectiveness analysis.Acute herpes zoster and post herpetic neuralgia in primary care: a study of diagnosis, treatment and cost.
P2860
Q26781940-8861C0B7-E85F-4B8B-8052-2542C73F47D6Q34291150-1D96A802-8199-4020-B001-0B398C817170Q35000186-FDED6A4E-63C3-4F96-928E-65E364C9EE2FQ35147612-48463785-7292-49CD-A827-1CBA275319B0Q35553149-9E86F35F-5E71-4F35-BA2E-7245E624C231Q35652212-6659B8D1-7EA3-4020-A34D-7BA118D2372CQ36615123-D22CA069-498E-4B62-BD3A-AEBE37B4F069Q38075493-9193B55F-6149-4124-A00A-605FE133EB18Q38120494-E2ECE316-3965-43F1-B6D7-FC515ECE727DQ38416454-3E25F5F6-775D-4A6C-B606-9C17B4DE2ECBQ38798312-127D5397-5ED4-4DDC-A310-CD13C4B1BFF9Q39394780-FF95BA67-0F86-4E44-BC4D-F5311334AADDQ40515774-F73DF951-FA53-4ADC-8670-A31979168BFBQ45937750-F9823C9C-9E67-44DC-ADA3-97AD0EC84D3FQ46941948-A06C87BA-3816-45C0-9FB2-C3BE7D2D5A00Q47346906-A1FD067B-F19A-4714-8F4B-6D49C92C5232
P2860
Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Economic evaluation of a vacci ...... n older adults in Switzerland.
@ast
Economic evaluation of a vacci ...... n older adults in Switzerland.
@en
type
label
Economic evaluation of a vacci ...... n older adults in Switzerland.
@ast
Economic evaluation of a vacci ...... n older adults in Switzerland.
@en
prefLabel
Economic evaluation of a vacci ...... n older adults in Switzerland.
@ast
Economic evaluation of a vacci ...... n older adults in Switzerland.
@en
P2093
P2860
P356
P1433
P1476
Economic evaluation of a vacci ...... n older adults in Switzerland.
@en
P2093
Anton Fendl
Jean-Pierre Michel
Manto Papageorgiou
Reto W Kressig
Thomas D Szucs
Werner Kempf
Xavier Bresse
P2860
P304
P356
10.4161/HV.7.7.15573
P577
2011-07-01T00:00:00Z